Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Abby Poms"'
Autor:
Sandeep Sahay, Vijay Balasubramanian, Humna Memon, Abby Poms, Eduardo Bossone, Kristine Highland, Dana Kay, Deborah J Levine, Christopher J Mullin, Lana Melendres‐Groves, Stephen C Mathai, Francisco J Soto, Oksana Shlobin, Jean M Elwing
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 2, Pp n/a-n/a (2022)
Abstract Pulmonary arterial hypertension (PAH) is a chronically progressive fatal disease. A goal‐oriented approach to achieve low risk status has been associated with improved survival. A variety of risk stratification tools are available, but use
Externí odkaz:
https://doaj.org/article/10dc882d91c940ca9de32b077a366fb3
Autor:
Aparna C. Swaminathan, Hongmei Zhu, Victor Tapson, Yuliya Lokhnygina, Abby Poms, Zach Kelleher, Elijah Gaspard, Karla Kennedy, Brian E. Fee, Terry Fortin, S. Nicholas Mason, Kishan Parikh, Tim J. McMahon
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-11 (2020)
Abstract Background Multiple classes of oral therapy are available for the treatment of pulmonary arterial hypertension (PAH), but there is little to guide clinicians in choosing a specific regimen or therapeutic class. We aimed to investigate whethe
Externí odkaz:
https://doaj.org/article/92fe33bd0f0a4461aeb63464bf07a18e
Autor:
Christine Y. Zhou, Sandeep Sahay, Oksana Shlobin, Francisco J. Soto, Stephen C. Mathai, Lana Melendres-Groves, Christopher J. Mullin, Deborah J. Levine, Dana Kay, Kristin Highland, Eduardo Bossone, Abby Poms, Humna Memon, Vijay Balasubramanian, Mary Jo S. Farmer, Franck Rahaghi, Jean M. Elwing
Publikováno v:
Respiratory medicine. 206
The coronavirus of 2019 (COVID-19) disrupted delivery of healthcare. Patients with pulmonary hypertension (PH), especially pulmonary arterial hypertension (PAH), require significant resources for both diagnosis and management and are at high risk for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cd588dc3dd77e024170722ef8dfd2d1
https://pubmed.ncbi.nlm.nih.gov/36493604
https://pubmed.ncbi.nlm.nih.gov/36493604
Autor:
Eric D. Austin, Nicholas S. Hill, Zeenat Safdar, Robert W. Simms, Abby Poms, William C. Nichols, Harrison W. Farber, Katie A. Lutz, K. Feldkircher, Robert P. Frantz, Terry Fortin, J. Badlam, R. James White, Charles D. Burger, Jean M. Elwing, Murali M. Chakinala, Raymond L. Benza, C. Gregory Elliott, Wendy K. Chung, Ivan M. Robbins, Michael W. Pauciulo, Chang Yu, Marc A. Simon, Sophia Airhart, David B. Badesch, Adaani E. Frost
Publikováno v:
Chest. 159:311-327
Background The treatment, genotyping, and phenotyping of patients with World Health Organization Group 1 pulmonary arterial hypertension (PAH) have evolved dramatically in the last decade. Research Question The United States Pulmonary Hypertension Sc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5b5527ee7104d421b422e123e20cbb8
https://doi.org/10.1016/j.chest.2020.07.088
https://doi.org/10.1016/j.chest.2020.07.088
Autor:
Sandeep Sahay, Vijay Balasubramanian, Humna Memon, Abby Poms, Eduardo Bossone, Kristine Highland, Dana Kay, Deborah J Levine, Christopher J Mullin, Lana Melendres‐Groves, Stephen C Mathai, Francisco J Soto, Oksana Shlobin, Jean M Elwing
Publikováno v:
Pulmonary circulation. 12(2)
Pulmonary arterial hypertension (PAH) is a chronically progressive fatal disease. A goal-oriented approach to achieve low risk status has been associated with improved survival. A variety of risk stratification tools are available, but use is low. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a328b6a87f5ea8c60acc5246db1e3d73
https://pubmed.ncbi.nlm.nih.gov/35514787
https://pubmed.ncbi.nlm.nih.gov/35514787
Autor:
Chang Yu, Katie A. Lutz, Raymond L. Benza, Wendy K. Chung, C. Gregory Elliott, Harrison W. Farber, Michael W. Pauciulo, K. Feldkircher, Eric D. Austin, J. Badlam, David B. Badesch, Adaani E. Frost, William C. Nichols, Abby Poms
Publikováno v:
Pulmonary Circulation, Vol 9 (2019)
Pulmonary Circulation
Pulmonary Circulation
Diagnostic World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) and Diagnostic Group 1' pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH) are progressive and fatal disorders. Past regist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cb13d01a5ccf94bd69d4bc676a96134
https://doi.org/10.1177/2045894019851696
https://doi.org/10.1177/2045894019851696
Autor:
Timothy J. McMahon, Terry Fortin, S. Nicholas Mason, Abby Poms, Elijah Gaspard, Hongmei Zhu, Yuliya Lokhnygina, Brian E. Fee, Karla Kennedy, Victor F. Tapson, Zach Kelleher, Kishan S. Parikh, Aparna Swaminathan
Publikováno v:
Respiratory Research
Respiratory Research, Vol 21, Iss 1, Pp 1-11 (2020)
Respiratory Research, Vol 21, Iss 1, Pp 1-11 (2020)
Background Multiple classes of oral therapy are available for the treatment of pulmonary arterial hypertension (PAH), but there is little to guide clinicians in choosing a specific regimen or therapeutic class. We aimed to investigate whether treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1158d0d3a1998aa3763441b68697503
https://doi.org/10.1186/s12931-020-01566-y
https://doi.org/10.1186/s12931-020-01566-y
Publikováno v:
Journal of Cardiovascular Pharmacology. 67:322-325
Pulmonary arterial hypertension (PAH) has emerging therapeutic options including prostacyclin analogs. Inhaled therapy offers advantages compared with alternative routes of administration. We aimed to determine the safety and tolerability of inhaled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36e4bba05e0ad706391743ba7f8f476c
https://doi.org/10.1097/fjc.0000000000000357
https://doi.org/10.1097/fjc.0000000000000357
Publikováno v:
Chest. 144:169-176
Background: Comorbidities can affect disease progression and/or response to treatment in various conditions. Comorbid conditions are prevalent in patients with pulmonary arterial hypertension (PAH); however, their effect on patient outcomes remains u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ff89d60fc2fa897147c04db727cb7ea
https://doi.org/10.1378/chest.11-3241
https://doi.org/10.1378/chest.11-3241
Publikováno v:
Advances in Pulmonary Hypertension. 10:246-252
In a departure from the usual composition of the roundtable—but still within the framework of a conversation among experts—guest editor Hap Farber assembled a panel of clinicians and patients to expand on the information available to providers co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4188dbd196b4f85eebeb888d52e042bc
https://doi.org/10.21693/1933-088x-10.4.246
https://doi.org/10.21693/1933-088x-10.4.246